Study design
This two-part, randomized, parallel-group phase 2a study was conducted sequentially between June 2018 and April 2021 at two study sites in Sweden and the Netherlands. Part A was an exploratory, double-blind, randomized, placebo-controlled study (Extended Data Fig. Eligible patients for both parts were adults with a BMI of 27–40 kg mThis study included both sexes; gender data were not collected. Owing to the small sample size, sex was not considered in the study design and data were not disaggregated for sex. Ethnicity, ancestry or any other socially relevant groupings were also not considered in the study design.